RNS Number : 6637R Hemogenyx Pharmaceuticals PLC

31 December 2024

31 December 2024

## Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

## **Total Voting Rights**

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 December 2024 consists of 3,504,539 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 3,504,539.

The figure of 3,504,539 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

## **Enquiries:**

 Hemogenyx Pharmaceuticals plc
 https://hemogenyx.com

 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
 headquarters@hemogenyx.com

 Peter Redmond, Director
 peter.redmond@hemogenyx.com

**SP Angel Corporate Finance LLP** Tel: +44 (0)20 3470 0470

 $Matthew\ Johnson,\ Vadim\ Alexandre,\ Adam\ Cowl$ 

Peterhouse Capital Limited Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREADAEDFKLFAA